Enthera's Approach To Type 1 Diabetes Attracts Corporate VCs
Large Series A For Italian Biotech
Executive Summary
Italy’s four-year-old Enthera Pharmaceuticals is developing antibodies targeted at restoring pancreatic beta cells in type 1 diabetes, and has attracted corporate investors to its series A funding.